Centessa Pharmaceuticals Plc ADR (CNTA) Stock Price, Quote & News

Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive...

Industry: Biotechnology

Sector: Healthcare

Website: centessa.com

Address:

1 Ashley Road, 3rd Floor, Altrincham, United Kingdom

TrendEdgeLogan Aug. 1 at 6:25 PM

If you're not looking at biotech stocks today idk what you are looking at. $XBI $IBB $ONC $CNTA $ASND KNSA, MIRM, ALNY, SPRY, XERS

0 · Reply

CrispDry Jul. 30 at 10:48 PM

$CNTA something very odd is going on. Call OI still there. Massive midday vol spike, 400% daily average. Just get it out overnight or in the morning $XBI

0 · Reply

CrispDry Jul. 30 at 8:51 PM

$CNTA the August 10 and 25 calls OI is still intact

0 · Reply

BaringsTrading Jul. 30 at 7:21 PM

$CNTA I see $20

1 · Reply

CrispDry Jul. 30 at 6:44 PM

$CNTA biggggg moves

0 · Reply

NVDAMillionaire Jul. 28 at 8:24 PM

$CNTA Great piece that accurately captures CNTA's current position. So if you want to refresh your understanding of CNTA or learn about CNTA for the first time, this is essential reading. https://beyondspx.com/article/centessa-pharmaceuticals-unpacking-the-asset-centric-engine-driving-orexin-ambitions-nasdaq-cnta

0 · Reply

CrispDry Jul. 24 at 7:44 PM

$CNTA this trading makes me physically ill

0 · Reply

Quantumup Jul. 21 at 7:58 PM

Truist🏁 $CNTA Buy/$30 $ALKS $TAK HRMY $JAZZ $AXSM Leerink reiterated $CNTA at an Outperform rating and says, $ALKS' narcolepsy trial results are encouraging for $CNTA Truist and Leerink said in their research reports:

0 · Reply

JarvisFlow Jul. 21 at 12:00 PM

Truist Securities has updated their rating for Centessa Pharmaceuticals ( $CNTA ) to Buy with a price target of 30.

0 · Reply

Quantumup Jul. 21 at 11:07 AM

Stifel $ALKS Buy-$42: "We are reiterating our Buy rating on $ALKS on the back of positive top-line data for ALKS2680/"Alixorexton" in Narcolepsy Type-1. Bottom line: this study was widely expected to succeed given prior ph1b data in NT1 and broader support via Takeda. Even still, the results here look clearly positive with many key clinical endpoints hitting statistical significance at all doses, with the exception of cataplexy attacks which "numerically improved" at all doses and only hit a p-value at the mid-dose (we await details, but probably a powering/variability issue). On safety, the disclosure was fairly high level, but 95% of patients who participated in the trial entered the OLE which is always encouraging. The PR specifically noted no treatment-related signals in hepatic/renal parameters, vital signs or ophthalmic exams, but we'll need to wait for full data to see if there were any mild visual AEs at all -- we remain generally unconcerned though." $TAK $BIIB $AXSM JAZZ $CNTA

0 · Reply

Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa's Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist

Jun 16, 2025, 9:00 AM EDT - 7 weeks ago

Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year

May 19, 2025, 8:00 AM EDT - 2 months ago

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

May 14, 2025, 7:00 AM EDT - 2 months ago

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025

Mar 24, 2025, 7:00 AM EDT - 4 months ago

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

Mar 6, 2025, 4:14 PM EST - 5 months ago

Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting

Jan 8, 2025, 7:05 AM EST - 7 months ago

Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer

Dec 26, 2024, 12:31 PM EST - 7 months ago

Centessa: Shift In Focus With ORX750 Development Continues To Pay Off

Nov 12, 2024, 7:00 AM EST - 9 months ago

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Sep 26, 2024, 6:00 AM EDT - 11 months ago

Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Sep 12, 2024, 10:34 PM EDT - 11 months ago

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Sep 11, 2024, 4:04 PM EDT - 11 months ago

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Sep 11, 2024, 6:52 AM EDT - 11 months ago

Nxera Pharma's Partner Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Sep 10, 2024, 7:00 AM EDT - 11 months ago

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Aug 27, 2024, 8:00 AM EDT - 1 year ago

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Aug 21, 2024, 8:00 AM EDT - 1 year ago

Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

Jun 10, 2024, 7:00 AM EDT - 1 year ago

Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer

May 13, 2024, 4:10 PM EDT - 1 year ago

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024

Apr 24, 2024, 2:20 PM EDT - 1 year ago

Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point

Apr 23, 2024, 9:36 PM EDT - 1 year ago

Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares

Apr 23, 2024, 4:17 PM EDT - 1 year ago

Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares

Apr 22, 2024, 7:00 AM EDT - 1 year ago

Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024

Mar 28, 2024, 4:28 PM EDT - 1 year ago

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023

Feb 9, 2024, 7:00 AM EST - 1 year ago

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and

Feb 5, 2024, 1:48 PM EST - 1 year ago

Centessa Pharmaceuticals: Clinical Advances And Unique Business Model Highlight Growth Potential

Dec 13, 2023, 8:00 AM EST - 1 year ago

Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference

Dec 10, 2023, 12:05 PM EST - 1 year ago

Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia

Nov 13, 2023, 4:05 PM EST - 1 year ago

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023

Nov 2, 2023, 9:09 AM EDT - 1 year ago

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting

Oct 31, 2023, 8:00 AM EDT - 1 year ago

Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors

Oct 25, 2023, 8:00 AM EDT - 1 year ago

Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750's Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders

Sep 14, 2023, 5:31 AM EDT - 2 years ago

Centessa Pharmaceuticals: A Diversified Bet In Underserved Markets

Aug 23, 2023, 5:08 PM EDT - 2 years ago

Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress

Aug 17, 2023, 11:58 AM EDT - 2 years ago

Centessa Pharmaceuticals: Pipeline Progresses As PRESent-2 Initiated

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023

Jul 10, 2023, 8:00 AM EDT - 2 years ago

Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors

May 22, 2023, 7:00 AM EDT - 2 years ago

Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B

May 12, 2023, 7:00 AM EDT - 2 years ago

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023

Mar 30, 2023, 7:00 AM EDT - 2 years ago

Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022

Mar 23, 2023, 4:30 PM EDT - 2 years ago

Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director

CLVT

Mar 1, 2023, 8:00 AM EST - 2 years ago

Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines

Feb 6, 2023, 8:00 AM EST - 2 years ago

Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)

Feb 2, 2023, 8:00 AM EST - 2 years ago

Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference

Jan 26, 2023, 9:08 AM EST - 2 years ago

Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors

Dec 10, 2022, 3:30 PM EST - 2 years ago

Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia

Nov 28, 2022, 10:30 PM EST - 2 years ago

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses to Contact the Firm

Nov 28, 2022, 11:30 AM EST - 2 years ago

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the Firm

Nov 25, 2022, 9:10 AM EST - 2 years ago

MONDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the Firm

TrendEdgeLogan Aug. 1 at 6:25 PM

If you're not looking at biotech stocks today idk what you are looking at. $XBI $IBB $ONC $CNTA $ASND KNSA, MIRM, ALNY, SPRY, XERS

0 · Reply

CrispDry Jul. 30 at 10:48 PM

$CNTA something very odd is going on. Call OI still there. Massive midday vol spike, 400% daily average. Just get it out overnight or in the morning $XBI

0 · Reply

CrispDry Jul. 30 at 8:51 PM

$CNTA the August 10 and 25 calls OI is still intact

0 · Reply

BaringsTrading Jul. 30 at 7:21 PM

$CNTA I see $20

1 · Reply

CrispDry Jul. 30 at 6:44 PM

$CNTA biggggg moves

0 · Reply

NVDAMillionaire Jul. 28 at 8:24 PM

0 · Reply

CrispDry Jul. 24 at 7:44 PM

$CNTA this trading makes me physically ill

0 · Reply

Quantumup Jul. 21 at 7:58 PM

0 · Reply

JarvisFlow Jul. 21 at 12:00 PM

Truist Securities has updated their rating for Centessa Pharmaceuticals ( $CNTA ) to Buy with a price target of 30.

0 · Reply

Quantumup Jul. 21 at 11:07 AM

0 · Reply

PhaseFlow Jul. 17 at 4:27 AM

$CNTA $PLXS On watch

1 · Reply

jozef56 Jul. 15 at 1:57 PM

$ALKS $BIIB $TAK $AXSM $CNTA also golman sacks has his own agenda ...never trust analysts

0 · Reply

Quantumup Jul. 15 at 1:18 PM

Goldman Sachs🏁 $ALKS But/$43. $BIIB $TAK $AXSM JAZZ $CNTA Goldman Sachs said in its initiation report:

0 · Reply

TrendEdgeLogan Jul. 9 at 5:54 PM

$XBI biotech crushing it in the favorite's list today. $CNTA $AXSM $MIRM $ONC

0 · Reply

TrendEdgeLogan Jul. 2 at 2:12 PM

$CNTA not too late here! Last call $XBI

0 · Reply

Stocktwits Jun. 26 at 2:11 AM

🚨 Chart of the Day by @DJRick - ATH Will Take Some Patience ⚠️ $SPY Get the hottest trade ideas and daily insights in your inbox with the Chart Art newsletter! https://chartart.stocktwits.com/p/stocktwits-chart-art-june-25-2025-4468ffc4223b78eb Also featured: @wha1e $GLD, @Dr_Stoxx $SMCI, @PazTeuR $RDDT, @TrendEdgeLogan $CNTA

2 · Reply

TrendEdgeLogan Jun. 25 at 10:11 PM

$CNTA is among my top three actionable swing-long setups tonight - $1.80B mkt cap $XBI biotech hidden gem (only 238 watchers on Stocktwits) - Showing reaccumulation above rising 10/80-week SMAs after a textbook 50% mean-reversion ($20-$10) retest - Monthly chart shows three long wicks and tight closes off the 20-month SMA and key $10 level, holding firm - Percentage of funds long at record highs, surging despite volatility Clear shot at $40 if biotech sector turns a new leaf $IBB TrendEdge.app/asset/CNTA

0 · Reply

swingingtech Jun. 10 at 12:37 PM

$TMSL $CNTA $KYMR $PRIM https://wallstreetwaves.com/we-did-the-math-tmsl-can-go-to-38/

0 · Reply

_www_larval_com_ Jun. 5 at 3:52 PM

$CNTA has reverted 3% higher to -4% (~2Mv) moments ago, 06/20 options, follow for more volatility.

0 · Reply

badhombre88 Jun. 5 at 3:32 PM

$CNTA 1.3 million brazy vol and 50% more than 10 day avg vol

0 · Reply

JarvisFlow May. 28 at 10:30 AM

Needham has adjusted their stance on Centessa Pharmaceuticals ( $CNTA ), setting the rating to Buy with a target price of 35.

0 · Reply

badhombre88 May. 27 at 7:20 PM

$CNTA 1.1mil brazy vol and 50% more than 10 day avg vol

0 · Reply

Market Cap	2.25B
Revenue (ttm)	0.00
Net Income (ttm)	-235.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.28

Volume	1,384,600
Avg Vol	1,105,434
Day's Range	N/A - N/A
Shares Out	133.62M
Stochastic %K	39%
Beta	1.47
Analysts	Strong Sell
Price Target	$31.90